# A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

> **NCT07218380** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 450 (estimated)

## Conditions studied

- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** Vepugratinib
- **OTHER:** Placebo
- **DRUG:** EV
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07218380
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2029-10
- **Final completion:** 2033-05
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07218380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07218380, "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07218380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*